Abstract: This invention is a preparation station for creating a certified reference material. The certified reference material is used to compare the air within an area or room. This is beneficial for identifying if the air within the area contains certain volatile compounds or otherwise undesired compounds. This is accomplished by providing a sealed ampule containing chemical compounds that is eventually broken by the gas preparation device. Once the ampule is broken a gas cylinder the contents are mixed with a diluent gas and forced into a reference material cylinder. The contents within the cylinder are verified and certified for use in testing the air quality of the area or room. Accordingly, with the use of a sealed premade ampule, this invention allows for creating a custom reference material as needed and also eliminates the need for shipping compressed gas cylinders for air quality testing.

Abstract: Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.

Abstract: Methods, apparatuses, and kits for detection of substances in water by forming a complex with an indicator reagent and filtering the complex on a filter or membrane are described. The concentrated indicator on the filter, membrane or other capture device provides a colorimetric readout that can determine the amount of substance present in a water sample. A computer-implemented method for determining the concentration of substances in water based on color data from the colorimetric readout is also described.

Abstract: An embodiment a pressure compensated pH sensor apparatus, including: a pH sensing component comprising a sensing portion that is exposed to a fluid source when in use; a pressure chamber located in a position under the sensing portion and that envelopes all of the sensing portion not exposed to the fluid source when in use; and a pressure compensation mechanism located within the pressure chamber, wherein the pressure compensation mechanism reacts to pressure from an environment outside the apparatus, thereby support the sensing portion.

Abstract: One object is to provide an industrial device in which abrasion powder (conductive substance) can accumulate on a sensor to an amount necessary for proper failure prediction. An industrial device according to an embodiment of the present invention includes: a lubricant reservoir portion including a region in which a lubricant circulates; and a sensor including a pair of electrodes disposed in the region in which the lubricant circulates, the sensor being configured to sense variation of electric resistance between the pair of electrodes.

Abstract: A method for separating particles in a biofluid includes pretreating the biofluid by introducing an additive, flowing the pretreated biofluid through a microfluidic separation channel, and applying acoustic energy to the microfluidic separation channel. A system for microfluidic separation, capable of separating target particles from non-target particles in a biofluid includes at least one microfluidic separation channel, a source of biofluid, a source of additive, and at least one acoustic transducer coupled to the microfluidic separation channel. A kit for microfluidic particle separation includes a microfluidic separation channel connected to an acoustic transducer, a source of an additive, and instructions for use.

Abstract: Provided herein are methods of detecting C5b-9 deposition on endothelial cells. The methods are useful for screening patients for complement-associated disorders, for example, atypical hemolytic-uremic syndrome, as well as monitoring the efficacy of anti-C5 antibody therapy in a patient with a complement-associated disorder.

Abstract: A method for identifying an AhR-phospho-ROR?t protein complex inhibitor, comprising: (a) providing a cell culture, in which cells in the culture express AhR protein and phospho-ROR?t protein; (b) incubating the cell culture in the presence of a test agent; (c) assaying the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent; (d) comparing the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent with a control; and (e) identifying the test agent as the inhibitor of the AhR-phospho-ROR?t protein complex when the comparing step indicates that there is a reduction in the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent as compared with the control. A method for identifying a GLK?IQGAP1 protein complex inhibitor is also disclosed. Use of identified inhibitors in the manufacture of a medicament for treating a disease is also disclosed.

Abstract: Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer.

Abstract: The present invention relates to a method for single-cell imaging mass spectrometry (MS) by correlating an optical image of a cell sample with an MS image. The method of the invention is in particular useful in research to test concomitantly optical and molecular phenotypes at a single-cell resolution.

Abstract: Systems, devices, and methods for monitoring and assessing immunotherapy toxicity are discussed. An exemplary system receives physiologic information from a patient using an ambulatory medical device. In response to an immunotherapy such as CAR T-cell therapy, the system determines a toxicity indication using the received physiologic information. A therapy can be initiated or adjusted using the toxicity indication.

Abstract: The present invention relates to cell-based methods for determining the biological activity of defibrotide. In particular, the invention provides a method for assessing the potency of defibrotide by assessing the viability of mammalian cells in the presence of at least one cytotoxic agent and one or more concentrations of defibrotide. Such methods are particularly useful for standardizing pharmaceutical compositions comprising defibrotide.

Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

Abstract: The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

Abstract: Described herein are methods of transdifferentiating preadipocytes, populations of transdifferentiated preadipocytes, and methods of using the transdifferentated preadipocytes.

Abstract: The invention relates to a nonspecific reaction inhibitor for an immunoassay containing an anti-mammal-derived IgM antibody in which, in ELISA assay, a ratio A2/A1 of an absorbance A2 which is obtained when a reaction of the anti-mammal-derived IgM antibody with cat IgM is carried out to an absorbance A1 which is obtained when a reaction of the anti-mammal-derived IgM antibody with dog IgM is carried out is 0.1 or more and 1.5 or less and in which, in ELISA assay, a ratio A3/A1 of an absorbance A3 which is obtained when a reaction of the anti-mammal-derived IgM antibody with human IgM is carried out to the absorbance A1 which is obtained when the reaction of the anti-mammal-derived IgM antibody with dog IgM is carried out is 0.5 or more, which can sufficiently inhibit a nonspecific reaction.

Abstract: According to one embodiment, a method of detecting or quantifying a detection target in a specimen includes: irradiating a reaction mixture with light to cause a flow of a liquid part of the reaction mixture, the reaction mixture containing: an affinity material including a carrier and an affinity substance that is carried on the carrier and has affinity to the detection target; a nanostirrer including a metal nanoparticle; and the specimen; and detecting or quantifying the detection target based on a complex composed of the affinity material and the detection target.

Abstract: Point-of-care (POC) testing for T. gondii infection can potentially address cost concerns and lead to better clinical outcomes through improved access to screening. This disclosure provides methods and compositions for whole blood POC testing to identify T. gondii infection with high sensitivity and specificity, obviating the need for venipuncture and sample processing infrastructure, making it an efficient, low-cost POC test.

Abstract: The present disclosure relates to protein-polymer conjugates comprising an engineered binding oligomer protein and a polymer for detection of a ligand of interest, methods, compositions and kits thereof.

Abstract: A specimen delivery cartridge includes a lower housing, and an upper housing. The upper housing is coupled to the lower housing at a hinge. The specimen delivery cartridge further comprises a testing chamber comprising a paper testing substrate. The paper testing substrate may include a wicking conduit and a plurality of test areas. The specimen delivery cartridge may also include a lens assembly proximate the plurality of test areas and operable to transmit light emissions from the plurality of test areas to an image sensor of a computing device. In some embodiments, the specimen delivery cartridge includes a testing substrate having a plurality of test areas made of an array of electrodes. Each electrode is printed on a first side of the testing substrate and coupled to a conductive via formed in the testing substrate and a conductive trace printed on a second, opposing side of the testing substrate.

Abstract: Methods and systems for improved labeling and/or de-labeling a molecule or cell in the context of scientific experimentation, industrial applications, and clinical investigation, including the means to repeat the process of labeling and de-labeling in an efficient manner.

Abstract: The invention provides a method for determining a systemic lupus erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table A, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table A is indicative of a systemic lupus. The invention also provides an array and a kit suitable for use in the methods of the invention.

Abstract: A use of an enhancer of rudimentary homolog (ERH) or a fragment thereof, in the preparation of a reagent for monitoring drug efficacy for rheumatoid arthritis, is provided. 35 proteins as candidate ACPA-negative RA autoantigens, 8 proteins as candidate autoantigens for predicting disease activity, and 6 proteins as candidate autoantigens for predicting treatment effect were screened by hybridizing high density protein chips with RA serum. Of the 6 proteins as candidate autoantigens for predicting treatment effect, one autoantigen, ERH, can successfully determine the effect of drug treatment on RA, and the AUC for predicting efficacy may be up to 0.733.

Abstract: A method for detecting a malaria infection whereby providing a mouth cleansing product to a user then asking the user to blow or breathe onto or into a capture mechanism, wherein the capture mechanism may contain a thioether detection mechanism such as Michler's Hydrol; and analyzing whether a thioether detection mechanism displays any loss of the thioether detection mechanism. The invention also discloses a kit for indicating the presence of malaria by instructing the user to exhale through a capture mechanism after using a mouth cleansing product, wherein the kit includes a thioether detection mechanism such as Michler's Hydrol.

Abstract: The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9+ B cells in a blood sample of the subject, b) comparing the level of CD9+ B cells measured at step a) with one or more reference values of the level of CD9+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).

Abstract: Provided are methods of identifying, visualizing and purifying proteases from a complex biological sample.

Abstract: Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.

Abstract: The present invention provides methods of detecting breast cancer or breast cancer cells comprising: (a) obtaining a liquid sample from a subject which sample comprises cells, microvesicles and/or exosomes; and (b) determining the presence of soluble or cell surface associated Cyr61 in the sample; wherein the liquid sample is selected from blood, and/or bone marrow aspirate and wherein the determination of the presence of Cyr61 comprises detection via ELISA.

Abstract: Provided herein are methods of determining the aggressiveness, prognosis and response to therapy for cancer, such as non-small cell lung carcinoma (NSCLC), which includes determining an expression level of one or a plurality of differentially expressed protein markers in an exosome sample from a subject. A method and agent for treating cancer are also provided.

Abstract: In certain embodiments, this application discloses methods for the diagnosis and prognosis of prostate cancer. In some embodiments, the invention takes advantage of the combinatorial utility of certain biomarkers to prognose and diagnose prostate cancer at an early stage. In certain embodiments, the methods described herein do not require the selection of cells from a particular tissue compartment, and are therefore suitable for analysis of cancer tissue in which compartmentalization is lost.

Abstract: The present invention relates to methods of diagnosing a liver disorder in a patient, as well as methods of monitoring the progression of a liver disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Abstract: Compounds of general formula I wherein Fc and Fc? may be the same or different and are substituted ferrocenyl moieties having at least one ring substituent selected from sulfur-containing groups, phosphorus-containing groups, iodo, chloro, silyl, fluoroalkyl groups containing two or more fluorine atoms, heteroaryl, substituted phenyl, and cyano, wherein if present as sole substituent the cyano group is located on the proximal cyclopentadienyl ring; X is a spacer, Y is a spacer, Z is a spacer; and R is a linker group. Compound I may be used to make labelled substrates, functionalised compounds for making labelled substrates and may be used as labels in an electrochemical assay.

Abstract: A bioassay for the detection of multiple target analytes that includes living immunocytes of a plurality of predetermined types; a signal-generating reporter within each immunocyte that is responsive to predetermined changes occurring within the immunocyte and that includes a bioluminescent protein linked to a fluorescent protein; a signal transduction pathway associated with each signal-generating reporter that is operative to induce the predetermined changes within each immunocyte; a detector element associated with the signal transduction pathway that is operative to trigger the signal transduction pathway; an analyte binding element associated with the detector element that is specific to both the detector element and a target analyte; and wherein upon the binding of an analyte binding element to which a target analyte is also bound to the detector element, the detector element triggers the signal transduction pathway causing the predetermined changes to occur within the living biological cell, thereby ca

Abstract: A method for determining an amino acid sequence of a polypeptide, including comprising: contacting a first sample containing the polypeptide with a first protease(e.g., Trypsin) to produce a first set of digested peptide fragments; fragmenting the first set of digested peptide fragments to produce a first set of fragmented peptide ions; determining masses of the first set of fragmented peptide ions; contacting a second sample containing the polypeptide with a second protease (e.g.

Abstract: Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of ?-gliadin 33-mer, ?-gliadin-17-mer, ?-gliadin-15-mer, ?-gliadin-17-mer, and glutenin 21-mer.

Abstract: A method for detection or monitoring status of silent brain ischemia (SBI) and cerebrovascular health. The assay reagents and methods described herein provide a specific indicator of cerebral microvascular disease, enabling clinicians to identify patients at risk for the development of SBI. A method of treating a subject having silent brain ischemia and/or metabolic syndrome comprises administering to the subject aspirin therapy, blood pressure therapy, body weight management, and/or a program of diet and exercise when levels of two or more SBI markers are elevated. Described herein are molecules that are produced by cerebral endothelial cells exposed to chronic vascular risk factors including obesity, hyperlipidemia, hypertension, and glucose intolerance. These stress molecules produced by cerebral endothelial cells are detectable in the serum and serve as diagnostic indicators of brain-specific endothelial cell damage and correlate with MRI indicators of silent stroke and impaired cognitive function.

Abstract: The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.

Abstract: Described herein are methods for quantifying lAIP levels in a sample (e.g., from a subject) using lAIP ligand-based assays. Also disclosed are methods for measuring lAIP-IAIP ligand complexes, and methods of evaluating, monitoring, and treating subjects using the aforementioned lAIP quantification methods.

Abstract: The present invention is the protein of melanotransferrin, or an encoding nucleic acid of same, for use in the diagnosis of Parkinson's disease (PD). The invention is a method of diagnosis of PD in a subject, for assessing the level of melanotransferrin in the saliva or in a saliva sample of the subject and determining whether the level is above or below a value of 8.6 ?g/ml, wherein a value below 8.6 ?g/ml is indicative of PD. Another aspect is a kit having at least one reagent, preferably an antibody, for the quantification of melanotransferrin in the saliva or in a saliva sample of a subject enabling the comparison of the quantification with a predetermined cut-off value.

Abstract: Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.

Abstract: Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

Abstract: This invention provides tools and methods that prevent a cancer cell from growing and reproducing more cancer cells in a diseased animal. When growth ceases the body's immune defenses are enabled to attack and destroy these cells if the cancer cell itself has not initiated its own natural apoptotic self-destruction processes. The tools and methods of the invention obstruct the metabolic adaptions required to support cancer growth. By addressing the increased rates of metabolism characteristic of all rapidly reproducing cancer cells using chemical and/or physical nanotechnology to identify, segregate, isolate these hypermetabolizing cells, the body's immune system and other natural defenses are empowered to further isolate and eliminate the diseased cells. The extreme growth rates required for their rapid reproduction involve massively increased rates of the biochemical reactions supporting the cancerous growth.

Abstract: Disclosed is a method for measuring cholesterol by using a cholesterol dependent cytolysin (CDC), which is a cholesterol binding protein, and an antibody specifically recognizing HDL-C or LDL-C. The method according to the subject matter is capable of rapidly measuring low density lipoproteins and high density lipoproteins at low cost, and thus can be effectively applied in various fields requiring the measurement of low density lipoproteins and high density lipoproteins.

Abstract: Methods and apparatus for performing diagnostic assays using recommendations based on one or more user input are described herein. In an embodiment, a system for diagnosing and testing a patient for one or more disease includes an assay apparatus configured to perform a plurality of different assays on a patient sample using a plurality of stored capture reagents, a user interface in operable communication with the assay apparatus, the user interface configured to allow input of a patient's symptoms, and a control unit in operable communication with the user interface, the control unit configured to (i) analyze a disease profile database based on the symptoms inputted into the user interface, (ii) output at least one recommended assay based on the analysis of the disease profile database, and (iii) cause the assay apparatus to perform the at least one assay using at least one of the plurality of capture reagents.

Abstract: The present patent of invention relates to a reader device for biological samples used in the field of remote laboratory tests (TLR), for clinical diagnostic purposes, based on an optimized design constituted by a cowling (C) with inlet port (OE) and with switch (I); by a holding support (SS) containing a mirror (ES), two batteries (BT), two reading illumination arrays (BIL), operational status illumination arrays (BIS) and an elevator support (SE); by an elevator (EL); by an electronics board (PE) with energy loading circuit (PE-1), with supply circuit (PE-2), with processor (PE-3), with Bluetooth® device (PE-4) and with position sensor (PE-5); and by a base (BA) with software that reads various types of biological samples, the present invention providing the advantages of: ease of use, optimized operating flows, ease of training, modularity, compactness, reduced size, portability, lightness of weight, ergonomic design, used-friendliness, enhanced practically and low cost

Abstract: Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Abstract: A sample collection and testing device for analyzing blood is provided that includes a controller, a fluid flow pathway, a pump configured to move fluid through the fluid pathway, and an optical fluid measurement element configured to measure a light intensity of the fluid in the fluid flow pathway. The controller is configured to: start the pump to move a blood sample in the fluid flow pathway, receive a signal from the optical fluid measurement element indicating a detection of a leading edge of the blood in the fluid flow pathway, stop the pump to stop the moving of the blood in the pathway, receive a plurality of light intensity measurements from the optical measurement element, each light intensity measurement measured at a corresponding point of time, and provide a mapping of the light intensity measurements into an indication of a coagulation of the blood sample over a time period.

Abstract: Reducing a sensitivity of an electromechanical sensor is presented herein. The electromechanical sensor comprises a sensitivity with respect to a variation of a mechanical-to-electrical gain of a sense element of the electromechanical sensor; and a voltage-to-voltage converter component that minimizes the sensitivity by coupling, via a defined feedback capacitance, a positive feedback voltage to a sense electrode of the sense element—the sense element electrically coupled to an input of the voltage-to-voltage converter component. In one example, the voltage-to-voltage converter component minimizes the sensitivity by maintaining, via the defined feedback capacitance, a constant charge at the sense electrode. In another example, the electromechanical sensor comprises a capacitive sense element comprising a first node comprising the sense electrode. Further, a bias voltage component can apply a bias voltage to a second node of the electromechanical sensor.

Abstract: A sensor assembly is disclosed. The sensor assembly includes a housing that includes a top housing and a bottom housing that clamp together. The sensor assembly also includes a printed circuit board assembly (PBA). The sensor assembly also includes at least one piece of elastic material that is located in between the top housing and the PBA and in between the bottom housing and the PBA. When the PBA is clamped in the housing, the sensor assembly allows the PBA to maintain alignment relative to the housing across different environments in order to enable proper operation of the sensor assembly. A top surface of the PBA and a bottom surface of the PBA each have at least one three-dimensional feature that is designed to increase friction with the elastic material.

Abstract: An apparatus for measuring a speed of a vehicle having an in-wheel motor includes a lock nut part fixed to an outer portion of a rotation shaft rotated by receiving power of the in-wheel motor, and restricting movement of a bearing part positioned outside the rotation shaft; a connection part coupled to the lock nut part; a magnet part having a magnetic force, and fixed to the connection part; and a speed sensor part installed to be separated from the magnet part, and measuring rotations of the magnet part.